Advanced melanoma

Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab )...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The...


In a letter published in the cancer journal Annals of Oncology, researchers led by Jean-Philippe Spano, at Pitie-Salpetriere Hospital AP-HP...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...


Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage...


The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the...


Updated data from the advanced non-small cell lung cancer ( NSCLC ) patient cohort of the ongoing phase 1/2 ECHO-202...


Updated data from the ongoing phase 1/2 ECHO-204 trial evaluating the safety and efficacy of Epacadostat, an oral selective IDO1...


Treatment with programmed death receptor-1 ( PD-1 ) antibodies is associated with high response rates in patients with advanced melanoma....


Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune...


The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of...


With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat...


Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving...


The FDA ( Food and Drug Administration ) has granted Priority Review for the New Drug Application ( NDA )...


The FDA ( Food and Drug Administration ) has granted accelerated approval for Keytruda ( Pembrolizumab ) to treat patients...